NasdaqCM - Nasdaq Real Time Price USD

BioLineRx Ltd. (BLRX)

0.6565 +0.0164 (+2.56%)
At close: April 19 at 4:00 PM EDT
0.6600 +0.00 (+0.53%)
After hours: April 19 at 7:04 PM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Philip A. Serlin CPA, M.B.A., CPA, MBA Chief Executive Officer 598k -- 1960
Ms. Mali Zeevi CPA, CPA Chief Financial Officer 374k -- 1976
Dr. Ella Sorani Ph.D. Chief Development Officer 452k -- 1968
Ms. Holly W. May M.B.A. President of BioLineRx USA 710k -- 1962
Mr. John Lacey Head of Corporate Communications & Investor Relations -- -- --
Ms. Tsipi Keren-Lehrer B.Sc., L.L.B. Head of BD & Strategic Advisor -- -- --
Mr. Raziel Fried Treasurer & Budgetary Control Director -- -- --

BioLineRx Ltd.

Modi’in Technology Park
2 HaMa’ayan Street
Hevel Modi'in, 7177871
Israel
972 8 642 9100 https://www.biolinerx.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
79

Description

BioLineRx Ltd., a pre-commercial-stage biopharmaceutical company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; and MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer, as well as licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Modi'in, Israel.

Corporate Governance

BioLineRx Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

Related Tickers

PLX Protalix BioTherapeutics, Inc.
1.1500
+1.77%
 
ENLV Enlivex Therapeutics Ltd.
1.3200
-5.71%
 
CANF Can-Fite BioPharma Ltd.
1.9800
+0.51%
 
KZR Kezar Life Sciences, Inc.
0.7900
+0.30%
 
EVGN Evogene Ltd.
0.6120
-4.37%
 
BCLI Brainstorm Cell Therapeutics Inc.
0.5320
+3.44%
 
PLUR Pluri Inc.
5.25
+3.96%
 
PPBT Purple Biotech Ltd
0.4550
-1.30%
 
GMDAQ Gamida Cell Ltd.
0.0173
+4.22%
 
OCUP Ocuphire Pharma, Inc.
1.6550
-0.90%